↓ Skip to main content

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, December 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

patent
2 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
79 Dimensions

Readers on

mendeley
62 Mendeley
Title
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
Published in
Cancer Chemotherapy and Pharmacology, December 2009
DOI 10.1007/s00280-009-1188-1
Pubmed ID
Authors

Michael B. Jameson, Danny Rischin, Mark Pegram, John Gutheil, Adam V. Patterson, William A. Denny, William R. Wilson

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 3%
United Kingdom 1 2%
Unknown 59 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 18%
Student > Ph. D. Student 9 15%
Student > Bachelor 8 13%
Student > Master 6 10%
Student > Doctoral Student 4 6%
Other 11 18%
Unknown 13 21%
Readers by discipline Count As %
Medicine and Dentistry 12 19%
Biochemistry, Genetics and Molecular Biology 10 16%
Chemistry 10 16%
Agricultural and Biological Sciences 9 15%
Pharmacology, Toxicology and Pharmaceutical Science 6 10%
Other 2 3%
Unknown 13 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 January 2021.
All research outputs
#4,972,158
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#244
of 2,501 outputs
Outputs of similar age
#27,923
of 169,889 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#2
of 20 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,889 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.